In this study for the first time, surface-enhanced Raman spectroscopy (SERS) and tip-enhanced infrared (TEIRA) nanospectrocopy together with a quartz crystal microbalance (QCM) are postulated as powerful tools for comprehensive qualitative and quantitative analyses of drug/metal nanocarrier conjugates. The development of efficient drug/carrier systems requires that the stability of the drug/carrier connection be estimated and the number of drug molecules immobilized on the carrier surface be determined. Thus, such a characterization study is highly desirable. Here, the SERS technique was applied to identify how erlotinib, a drug applied in non-small cell lung cancer (NSCLC) therapy, interacts with silver nanoparticles (AgNPs) that are considered as drug carriers. These investigations indicate that in the erlotinib/AgNP suspension, the drug strongly connects with the NPs mainly through the phenylacetylene moiety. The QCM was used to prepare an AgNP monolayer with a monitored degree of coverage and to perform controlled erlotinib adsorption as a next step. The results indicate that the drug forms a stable layer on the AgNP monolayer and also show the amount of the erlotinib molecules which underwent immobilization on the metal nanosurface. Simultaneously, it was identified how the erlotinib layer adsorbs on the AgNP monolayer using TEIRA nanospectroscopy with ultra-high spatial resolution. The obtained results show that the phenylacetylene, ethoxy, and methoxy moieties are mainly responsible for the drug/AgNP monolayer connection. Additionally, the performed studies also try to explain the surface-enhanced phenomena that occur during the TEIRA experiments and attempt to prove the statement that the "tip-enhanced" effect plays a crucial role in the detection of the thin erlotinib layer deposited on the AgNP monolayer.